GT Biopharma (GTBP) SEC Filings: History & Chart

GT Biopharma, Inc.(GTBP)

Biotechnology · San Francisco, CA

$6.37+0.21 (+3.41%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About GT Biopharma, Inc.

GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.

San Francisco, CA

1 employees

www.gtbiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Martin Breen

View full financials

Form	Filing Date	Accepted	Document
PRE 14A	Oct 2, 2026	Oct 2, 2026	View filing
D	Sep 29, 2026	Sep 29, 2026	View filing
8-K	Sep 25, 2026	Sep 25, 2026	View filing
8-K	Sep 21, 2026	Sep 21, 2026	View filing
SC 13G	Sep 15, 2026	Sep 15, 2026	View filing
8-K	Sep 15, 2026	Sep 15, 2026	View filing
8-K	Sep 3, 2026	Sep 3, 2026	View filing
8-K	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 14, 2026	Aug 14, 2026	View filing
DEF 14A	Jul 2, 2026	Jul 2, 2026	View filing
PRE 14A	Jun 18, 2026	Jun 18, 2026	View filing
8-K	Jun 12, 2026	Jun 12, 2026	View filing
8-K	May 22, 2026	May 22, 2026	View filing
10-Q	May 15, 2026	May 15, 2026	View filing
EFFECT	May 13, 2026	May 14, 2026	View filing
424B3	May 13, 2026	May 13, 2026	View filing
S-1	Apr 30, 2026	Apr 30, 2026	View filing
8-K	Apr 7, 2026	Apr 7, 2026	View filing
10-Q/A	Mar 6, 2026	Mar 6, 2026	View filing
10-Q/A	Mar 6, 2026	Mar 6, 2026	View filing
10-K	Mar 2, 2026	Mar 2, 2026	View filing
8-K	Mar 2, 2026	Mar 2, 2026	View filing
EFFECT	Jan 30, 2026	Feb 2, 2026	View filing
424B3	Jan 30, 2026	Jan 30, 2026	View filing
S-1	Jan 21, 2026	Jan 21, 2026	View filing
424B3	Jan 8, 2026	Jan 8, 2026	View filing
EFFECT	Dec 2, 2025	Dec 3, 2025	View filing
424B3	Dec 2, 2025	Dec 2, 2025	View filing
8-K	Nov 26, 2025	Nov 26, 2025	View filing
10-Q	Nov 14, 2025	Nov 14, 2025	View filing

SEC Filings

Recent Filings